Crinetics Pharmaceuticals (CRNX)
(Delayed Data from NSDQ)
$56.06 USD
-0.97 (-1.70%)
Updated Nov 22, 2024 03:59 PM ET
After-Market: $56.05 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRNX 56.06 -0.97(-1.70%)
Will CRNX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Other News for CRNX
Promising Outlook for Crinetics Pharmaceuticals’ Paltusotine in Phase 3 Trial Drives Buy Rating
Ikarian Capital, LLC Adjusts Stake in iBio Inc
Steven Cohen's Recent Transaction in Crinetics Pharmaceuticals Inc
EcoR1 Capital, LLC Increases Stake in Aligos Therapeutics Inc
EcoR1 Capital, LLC Increases Stake in Xencor Inc